Gefires 250mg Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.

Gefires 250mg Tablet is used to treat different types of cancer

Uses of Gefires Tablet

Non-small cell lung cancer

Benefits of Gefires Tablet

In Non-small cell lung cancer

Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Gefires 250mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

Side effects of Gefires Tablet

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Gefires

Diarrhea
Dry skin
Loss of appetite
Nausea
Rash
Stomatitis (Inflammation of the mouth)
Vomiting
Weakness
Weight loss

How to use Gefires Tablet

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Gefires 250mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

Safety advice

Alcohol

UNSAFE

It is unsafe to consume alcohol with Gefires 250mg Tablet.

Pregnancy

CONSULT YOUR DOCTOR

Gefires 250mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding

CONSULT YOUR DOCTOR

Gefires 250mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving

UNSAFE

Gefires 250mg Tablet may cause side effects which could affect your ability to drive.
Gefires 250mg Tablet may make you feel weak. This may affect your driving ability.

Kidney

CAUTION

Gefires 250mg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Gefires 250mg Tablet may be needed. Please consult your doctor.

Liver

SAFE IF PRESCRIBED

Gefires 250mg Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Gefires 250mg Tablet may not be needed in these patients. Please consult your doctor.

All substitutes

For informational purposes only. Consult a doctor before taking any medicines.

Gefires 250mg Tablet

₹113.33/Tablet

Geftinat 250mg Tablet

Natco Pharma Ltd

₹196.67/tablet

74% costlier

Geftib Tablet

Glenmark Pharmaceuticals Ltd

₹126.43/tablet

12% costlier

Geftistar 250mg Tablet

Lupin Ltd

₹123.03/tablet

9% costlier

Chemogef 250mg Tablet

Neon Laboratories Ltd

₹98/tablet

14% cheaper

Gefitero Tablet

Hetero Drugs Ltd

₹315.4/tablet

178% costlier

View all substitutes

Quick tips

Gefires 250mg Tablet helps treat non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
Take it with or without food, preferably at the same time each day.
Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after taking this medicine.
Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
Inform your doctor if you develop ulceration in your mouth, changes in your vision or if you experience a worsening cough, shortness of breath, or breathing difficulties while taking this medicine.
Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.

Fact Box

Chemical Class

Quinazolinamines

Habit Forming

Therapeutic Class

ANTI NEOPLASTICS

Action Class

Tyrosine kinase inhibitors

Patient concerns

What is the purpose of Chemotherepy given at the time of radiotherapy in ca lung small cell carcinoma

Dr. Vijay Sharnangat

Medical Oncology and Hematology

This is given to enhance the therapeutic effect of radiation therapy which is curative for small cell lung cancer.

Right lung tumour cancer in upper portion In jalgaon district which oncologist is best for lung cancer.

Dr. Vijay Sharnangat

Medical Oncology and Hematology

Dr Nitin Chaudhari us best oncologist

My father in law is a lung cancer patient.He had gone through two chemo cycles.The first one led to a significant reduction of about 50% in the tumor size.He was administered gemcitabine and carboplatin.However,the 2nd one was ineffective.Please advise as to what could be the next course of action. He was a smoker and has non-small cell carcinoma.The cancer has spread to the adrenal glands.

Dr. Sanjay Singh Rai

Medical Oncology and Hematology

U have to do a CT SCAN 3WKS AFTER 3RD CHEMOBased on that u make assessment of response

Want to share the information?

Disclaimer:

Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

References

Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35.
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55.
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17.
Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 [revised 23 Apr. 2018]. [Accessed 232 Jan. 2019] (online) Available from:
Drugs.com. Gefitinib Pregnancy and Breastfeeding Warnings. [Accessed 27 Mar. 2019] (online) Available from:
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Gefitinib. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from:
Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:

Marketer details

Name: Resonance Laboratories Pvt Ltd

Address: 1, Noor Mahal, 19-D, Turner Road, Bandra, Mumbai-400050

Country of origin: India

The list of available options shown with the same composition has been prepared upon the advice of registered medical practitioners, pharmacists affiliated with TATA 1MG. TATA 1MG does not promote any pharmaceutical product of any particular company, and all recommendations are based on the medical opinion, advisories from specialist medical and pharmaceutical professionals.